Genomic and proteomic studies of medulloblastoma samples helped researchers characterize new cancer subtypes and targets.
New research proposes a novel mechanism for how tumors sidestep the immune system in patients with intracranial tumors.
The FDA based its approval on findings from a single-arm phase 2 study, in which researchers treated 68 patients with iobenguane I 131 intravenous injection.
Details for evaluating insomnia and a list of the major categories of sleep disorders.
EGFR-amplified tumors had a high rate of response.
Researchers enrolled 66 patients with glioblastoma to evaluate the safety and efficacy of upfront temozolomide with bevacizumab.
A previous study demonstrated that tumor-treating field therapy improves progression-free survival and overall survival among patients with glioblastoma.
Short-term incidence of leukemia, lymphoma, and brain cancer may be higher in children who were hospitalized with pneumonia.
Over 75% and 73.9% of VEGFi-naive and patients previously treated with a VEGFi, respectively, had at least 1 grade 3 or worse adverse event.
TTFs can be self-administered at home by patients; this novel radiation treatment is non-ionizing and delivers electrical fields directly to the brain.
Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.
Researchers reviewed data from 1722 patients diagnosed with meningioma between 2006 and 2013 to determine whether the growth itself and/or treatment reduce patient QoL.
Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.
First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.
At the preplanned interim analysis, the study was discontinued for futility.
Overall, 54% of patients in the non-adjuvant temozolomide arm had disease progression vs 39% of the adjuvant temozolomide arm.
The US Food and Drug Administration granted orphan drug status to SurVaxM for patients with glioblastoma.
Researchers at the University of Miami in Florida are evaluating whether a partially matured dendritic cell vaccine is safe and effective for patients with glioma or glioblastoma.
With vaccine treatment, 4 patients had not progressed for more than 4.9 years and 3 patients had not progressed more than 7 years post-diagnosis.
Researchers are attempting to determine the clinical efficacy of ICT-107, a dendritic cell vaccine, among patients with newly diagnosed glioblastoma.
Practice patterns for the management of patients with more than 3 brain metastases appear to vary widely among radiation oncologists.
Rapid administration of rituximab over 90 minutes was safe and feasible for patients with primary central nervous system (CNS) lymphoma.
Onartuzumab does not improve clinical outcomes for patients with glioblastoma when given with bevacizumab.
Dabrafenib is active and well-tolerated among patients with BRAF V600 mutation-positive pediatric low-grade glioma.
Among patients with 1 to 3 brain metastases, use of stereotactic radiosurgery (SRS) may result in less cognitive deterioration at 3 months.
Two novel regimens showed significant anti-tumor activity in patients with neuroblastoma.
The MATRix regimen may be the new standard chemoimmunotherapy for the treatment of central nervous system (CNS) lymphoma.
Treatment of primary central nervous system lymphoma with methotrexate, TMZ, and rituximab, followed by hWBRT and subsequent TMZ was safe.
New data from a phase 2 study of rindopepimut in patients with EGFRvIII-positive recurrent GBM showed a marked benefit in terms of overall survival.
BRCA1 protein expression may be an important predictive biomarker of overall survival in glioblastoma multiforme (GBM).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?